National Research Corporation logo
National Research Corporation NRC
$ 25.18 0.52%
report update icon

Quarterly report 2026-Q3
added 11-04-2026

National Research Corporation Net Income | NRC

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income National Research Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008
11.6 M 24.8 M 31 M 31.8 M 37.5 M 37.3 M 32.4 M 30 M 22.9 M 20.5 M 17.6 M 18.2 M 15.5 M 15.1 M 11.6 M 11.6 M 8.49 M -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
37.5 M 8.49 M 22.2 M

Quarterly Net Income National Research Corporation

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
4.7 M -3.3 M 3.09 M 1.68 M 3.99 M -190 K 5.79 M 6.56 M 5.69 M 6.17 M 6.36 M 8.86 M 7.87 M 7.27 M 6.96 M 6.64 M 8.29 M 8.32 M 8.53 M 9.63 M 9.65 M 8.94 M 9.23 M 8.21 M 9.56 M 7.7 M 11.7 M 8.78 M 8.09 M 7.37 M 8.17 M 7.8 M 6.99 M 7.95 M 7.31 M 6.52 M 4.15 M 5.75 M 6.52 M 5.72 M 4.73 M 4.56 M 5.51 M 5.93 M 4.14 M 4.06 M 3.48 M 4.1 M 4.55 M 4.05 M 5.45 M 3.77 M 3.81 M 3.43 M 4.47 M 3.7 M 3.58 M 3.94 M 3.85 M 3.13 M 2.65 M 2.33 M 3.46 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
11.7 M -3.3 M 5.74 M

References

  1. Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Diagnostics research industry

Issuer Net Income Price % 24h Market Cap Country
Motus GI Holdings Motus GI Holdings
MOTS
-12.9 M - -34.28 % $ 263 K israelIsrael
Biodesix Biodesix
BDSX
-35.3 M $ 7.55 -9.1 % $ 57 M usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
-21.6 M - -20.0 % $ 1.06 M usaUSA
Agilent Technologies Agilent Technologies
A
1.3 B $ 169.82 -3.21 % $ 48.2 B usaUSA
Charles River Laboratories International Charles River Laboratories International
CRL
-144 M $ 314.38 -4.13 % $ 15.6 B usaUSA
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
992 M $ 257.78 -0.4 % $ 28.6 B usaUSA
Danaher Corporation Danaher Corporation
DHR
3.61 B $ 220.3 -3.19 % $ 157 B usaUSA
DexCom DexCom
DXCM
836 M $ 79.02 -1.46 % $ 30.8 B usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
-10.9 M $ 2.44 -6.15 % $ 79.2 K usaUSA
Celcuity Celcuity
CELC
-177 M $ 53.32 -5.31 % $ 2.49 B usaUSA
Guardant Health Guardant Health
GH
-416 M $ 145.9 0.21 % $ 18.3 B usaUSA
BioNano Genomics BioNano Genomics
BNGO
-26.4 M $ 0.82 -7.56 % $ 4.46 M usaUSA
Bioventus Bioventus
BVS
22.7 M $ 9.89 -0.65 % $ 659 M usaUSA
IQVIA Holdings IQVIA Holdings
IQV
1.36 B $ 245.67 -1.92 % $ 42.2 B usaUSA
Laboratory Corporation of America Holdings Laboratory Corporation of America Holdings
LH
877 M $ 367.68 -0.44 % $ 30.6 B usaUSA
Castle Biosciences Castle Biosciences
CSTL
-24.2 M $ 32.69 -2.14 % $ 948 M usaUSA
Mettler-Toledo International Mettler-Toledo International
MTD
869 M $ 1 667.59 -2.3 % $ 34.4 B schweizSchweiz
Illumina Illumina
ILMN
850 M $ 192.79 -3.92 % $ 29.9 B usaUSA
Natera Natera
NTRA
-208 M $ 273.11 -5.8 % $ 37.3 B usaUSA
Koninklijke Philips N.V. Koninklijke Philips N.V.
PHG
897 M $ 28.63 -2.22 % $ 27.1 B niderlandNiderland
Fulgent Genetics Fulgent Genetics
FLGT
-60.5 M $ 24.03 -3.03 % $ 740 M usaUSA
CareDx, Inc CareDx, Inc
CDNA
-21.4 M $ 69.9 -2.81 % $ 3.72 B usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
-1.81 M - - $ 562 M britainBritain
Biomerica Biomerica
BMRA
-3.78 M $ 1.09 -0.46 % $ 3.18 M usaUSA
Interpace Biosciences Interpace Biosciences
IDXG
24.6 M $ 4.4 -4.35 % $ 19.5 M usaUSA
Lantheus Holdings Lantheus Holdings
LNTH
234 M $ 102.12 0.01 % $ 6.89 B usaUSA
Senseonics Holdings Senseonics Holdings
SENS
-69.1 M $ 8.03 -9.88 % $ 335 M usaUSA
Sotera Health Company Sotera Health Company
SHC
77.9 M $ 15.92 -1.82 % $ 4.52 B usaUSA
Fluidigm Corporation Fluidigm Corporation
FLDM
-53 M - 1.08 % $ 308 M usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
229 M $ 186.79 -1.88 % $ 14.6 B irlandaIrlanda
Co-Diagnostics Co-Diagnostics
CODX
-46.9 M $ 0.13 -22.11 % $ 173 K usaUSA
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
197 M - - $ 10.7 B usaUSA
Thermo Fisher Scientific Thermo Fisher Scientific
TMO
6.72 B $ 668.26 -2.95 % $ 252 B usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
-41.7 M $ 1.31 -9.02 % $ 5.22 M israelIsrael
Myriad Genetics Myriad Genetics
MYGN
-366 M $ 5.47 -1.26 % $ 507 M usaUSA
Precipio Precipio
PRPO
-363 K $ 17.46 -5.6 % $ 28 M usaUSA
ENDRA Life Sciences ENDRA Life Sciences
NDRA
160 K $ 3.58 -3.38 % $ 4.74 M usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
425 M $ 49.28 -0.72 % $ 10.7 B niderlandNiderland
NeoGenomics NeoGenomics
NEO
-108 M $ 14.8 -1.95 % $ 1.9 B usaUSA
OPKO Health OPKO Health
OPK
-226 B $ 1.58 -2.17 % $ 1.19 B usaUSA
Pacific Biosciences of California Pacific Biosciences of California
PACB
-546 M $ 1.64 -7.1 % $ 492 M usaUSA
Neogen Corporation Neogen Corporation
NEOG
-7.9 M $ 10.45 -3.73 % $ 2.27 B usaUSA
Personalis Personalis
PSNL
-81.3 M $ 14.29 -2.96 % $ 1.28 B usaUSA
Quidel Corporation Quidel Corporation
QDEL
810 M $ 8.31 -6.84 % $ 350 M usaUSA
Centogene N.V. Centogene N.V.
CNTG
-35.5 M - -6.23 % $ 30.6 M germanyGermany
Waters Corporation Waters Corporation
WAT
643 M $ 438.11 -4.11 % $ 26.1 B usaUSA
Neuronetics Neuronetics
STIM
-39 M $ 1.24 -4.44 % $ 81.8 M usaUSA
Trinity Biotech plc Trinity Biotech plc
TRIB
-31.2 M $ 6.24 13.76 % $ 2.24 B irlandaIrlanda
Exagen Exagen
XGN
-20 M $ 3.59 -5.53 % $ 77.4 M usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
501 M - - $ 399 M chinaChina